ovarian cancer

Repare Therapeutics eyes Phase III cancer study after Mythic trial success
Clinical Trials Arena
Fri, 12/13/24 - 11:48 am
Repare Therapeutics
clinical trials
endometrial cancer
ovarian cancer
Lunre+Camo
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Yahoo/Benzinga
Mon, 12/9/24 - 11:06 am
Merck
Keytruda
Lynparza
ovarian cancer
clinical trials
AbbVie bags EU nod for key drug from ImmunoGen takeover
Pharmaphorum
Mon, 11/18/24 - 11:10 am
AbbVie
Europe
Elahere
ovarian cancer
Immunogen
FDA grants fast track status for Volastra’s VLS-1488 to treat ovarian cancer
Pharmaceutical Business Review
Thu, 10/3/24 - 10:40 am
Volastra Therapeutics
VLS-1488
ovarian cancer
platinum-resistant ovarian cancer
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
BioPharma Dive
Wed, 09/4/24 - 11:46 am
Arsenal Bio
funding
biotech
cell therapy
ovarian cancer
kidney cancer
Roche
Bristol Myers Squibb
Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results
Tip Ranks
Tue, 07/30/24 - 11:48 am
Imunon
clinical trials
IMNN-001
ovarian cancer
Zentalis' shares plunge 30% after FDA places WEE1 drug on partial hold over sepsis deaths
Fierce Biotech
Tue, 06/18/24 - 11:30 am
Zentalis
patient deaths
clinical trials
azenosertib
platinum-resistant ovarian cancer
ovarian cancer
Oregon jury says Johnson & Johnson must pay $260M in mesothelioma talc case
Fierce Pharma
Tue, 06/4/24 - 11:27 pm
JNJ
legal
ovarian cancer
mesothelioma
Oregon
Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab
Fierce Biotech
Fri, 05/31/24 - 10:52 am
Galapagos
Adaptimmune
biobucks
t-cell therapies
uza-cel
ovarian cancer
J&J advances $6.48 billion settlement of talc cancer lawsuits
Reuters
Wed, 05/1/24 - 11:16 pm
JNJ
talc
legal
ovarian cancer
settlements
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
Biopharma Reporter
Thu, 04/25/24 - 11:36 am
AstraZeneca
PARP inhibitors
Merck
Lynparza
ovarian cancer
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
Pharma Voice
Thu, 04/4/24 - 11:18 am
Verastem Oncology
Pharma CEOs
ovarian cancer
Daniel Paterson
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
Clinical Trials Arena
Thu, 04/4/24 - 10:53 am
Daiichi Sankyo
Merck
ovarian cancer
clinical trials
raludotatug deruxtecan
R-DXd
J&J can contest evidence linking its talc to cancer, US judge rules
Reuters
Thu, 03/28/24 - 11:14 am
JNJ
legal
talc
ovarian cancer
FDA grants full approval to AbbVie's ovarian cancer therapy
Reuters
Sun, 03/24/24 - 10:25 pm
AbbVie
ovarian cancer
Elahere
PhotonPharma receives FDA clearance for ovarian cancer vaccine trial
Clinical Trials Arena
Wed, 03/6/24 - 11:42 am
Photon Pharma
FDA
clinical trials
Innocell
vaccines
ovarian cancer
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments
Fierce Biotech
Fri, 02/2/24 - 11:57 am
Allarity Therapeutics
Novartis
kidney cancer
ovarian cancer
dovitinib
After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial
Fierce Biotech
Mon, 01/29/24 - 10:27 pm
Laekna
afuresertib
clinical trials
ovarian cancer
GSK
Novartis
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Fierce Pharma
Thu, 11/30/23 - 10:20 am
AbbVie
M&A
antibody-drug conjugate
Immunogen
Elahere
ovarian cancer

Pages